Pathway to Polio Virulence Revealed

Using epidemiological and laboratory data, scientists have mapped out a sequence of mutations through which the attenuated oral polio vaccine reverts to a virulent virus.

Written byAshley P. Taylor
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Illustration of a single poliovirus virionCDC, MEREDITH BOYTER NEWLOVE, JAMES ARCHERPolio is nearly eradicated. Now much of the risk of polio outbreaks comes not from wild poliovirus but from the oral vaccine, which comprises attenuated viruses. These viruses accumulate mutations that allow them to circulate among under-vaccinated populations, regain virulence, and even cause outbreaks. Now, scientists have mapped out a series of mutations that might explain how some cases of vaccine-derived polio can arise, according to a study published today (March 23) in Cell.

Using data from outbreaks of this circulating vaccine-derived poliovirus, researchers at University of California, San Francisco (UCSF), and Tel-Aviv University, in collaboration with others, have identified genetic changes through which they believe the attenuated oral polio vaccine re-evolves virulence. An attenuated vaccine virus genetically engineered to carry the virulence mutations that the researchers identified caused paralysis in mice.

“In polio, we know that viruses that are more replicatively fit in cell culture are usually more paralytic in humans, or more paralytic in mice, for that matter, but it’s been a qualitative relationship,” Mike Famulare, who works on polio at the Institute for Disease Modeling in Washington and was not involved in the study, told The Scientist.

In the past, all three oral polio vaccine (OPV) ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies